MX2019010986A - Yap activo dominante, un efector de hippo, induce la accesibilidad a la cromatina y la renovación de cardiomiocitos. - Google Patents

Yap activo dominante, un efector de hippo, induce la accesibilidad a la cromatina y la renovación de cardiomiocitos.

Info

Publication number
MX2019010986A
MX2019010986A MX2019010986A MX2019010986A MX2019010986A MX 2019010986 A MX2019010986 A MX 2019010986A MX 2019010986 A MX2019010986 A MX 2019010986A MX 2019010986 A MX2019010986 A MX 2019010986A MX 2019010986 A MX2019010986 A MX 2019010986A
Authority
MX
Mexico
Prior art keywords
yap
accessiblity
dominant active
induces chromatin
hippo
Prior art date
Application number
MX2019010986A
Other languages
English (en)
Spanish (es)
Inventor
Monroe Tanner
Leach John
f martin James
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of MX2019010986A publication Critical patent/MX2019010986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Environmental Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
MX2019010986A 2017-03-14 2018-03-14 Yap activo dominante, un efector de hippo, induce la accesibilidad a la cromatina y la renovación de cardiomiocitos. MX2019010986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471204P 2017-03-14 2017-03-14
PCT/US2018/022496 WO2018170172A1 (en) 2017-03-14 2018-03-14 Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal

Publications (1)

Publication Number Publication Date
MX2019010986A true MX2019010986A (es) 2020-02-05

Family

ID=63523973

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019010986A MX2019010986A (es) 2017-03-14 2018-03-14 Yap activo dominante, un efector de hippo, induce la accesibilidad a la cromatina y la renovación de cardiomiocitos.
MX2022011881A MX2022011881A (es) 2017-03-14 2019-09-13 Yap activo dominante, un efector de hippo, induce la accesibilidad a la cromatina y la renovacion de cardiomiocitos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011881A MX2022011881A (es) 2017-03-14 2019-09-13 Yap activo dominante, un efector de hippo, induce la accesibilidad a la cromatina y la renovacion de cardiomiocitos.

Country Status (10)

Country Link
US (3) US11484553B2 (enExample)
EP (1) EP3595642A4 (enExample)
JP (3) JP2020513810A (enExample)
CN (2) CN116003564A (enExample)
AU (2) AU2018234632B2 (enExample)
BR (1) BR112019018912A2 (enExample)
CA (1) CA3056231A1 (enExample)
IL (2) IL308112B2 (enExample)
MX (2) MX2019010986A (enExample)
WO (1) WO2018170172A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3634495A4 (en) * 2017-06-01 2021-02-24 Baylor College of Medicine Dystrophin glycoprotein complex sequesters yap to inhibit cardiomyocyte proliferation
US11179479B2 (en) 2018-01-05 2021-11-23 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
WO2021119030A1 (en) * 2019-12-09 2021-06-17 Animatus Biosciences, Llc Enhanced cardiomyocyte regeneration
US20210324412A1 (en) * 2020-04-15 2021-10-21 University Of Southern California Activation of yap signaling for sensory receptor regeneration
CN111778281B (zh) * 2020-07-17 2021-04-23 四川省人民医院 一种视网膜双极细胞病变模型的构建方法及其应用
US20230193267A1 (en) * 2021-10-19 2023-06-22 Animatus Biosciences, Inc. Cardiac cell proliferation by administering inhibitors of sav1, nf2, mob1 and/or mutant srf
WO2024168269A1 (en) * 2023-02-10 2024-08-15 Baylor College Of Medicine Use of mutant yap for improving cardiac function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
TW563139B (en) 2000-11-30 2003-11-21 Nec Tokin Corp Magnetic core including magnet for magnetic bias and inductor component using the same
US8140593B2 (en) * 2008-05-15 2012-03-20 Microsoft Corporation Data viewer management
KR101057116B1 (ko) 2008-06-17 2011-08-16 한국과학기술원 포유류에서의 분화 조절제 및 분화 조절 방법
AU2013243952A1 (en) * 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10772974B2 (en) * 2013-11-18 2020-09-15 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
CN103705505A (zh) * 2013-12-19 2014-04-09 清华大学深圳研究生院 辛伐他汀的新用途
US20160361340A1 (en) * 2014-02-11 2016-12-15 Inetitut Pasteur Treatment of cardiac diseases with modulators of the hippo pathway
US20170246215A1 (en) * 2014-09-16 2017-08-31 Albert Einstein College Of Medicine, Inc. Repopulation of organs and tissues using a yap-ert2 fusion protein
GB201819659D0 (en) * 2018-12-03 2019-01-16 Vib Vzw Cancer regression by inducing a regeneration-like reponse

Also Published As

Publication number Publication date
BR112019018912A2 (pt) 2020-04-14
CN110520112A (zh) 2019-11-29
US20230063735A1 (en) 2023-03-02
IL308112A (en) 2023-12-01
JP2024073571A (ja) 2024-05-29
IL269187B2 (en) 2024-04-01
US20250073276A1 (en) 2025-03-06
WO2018170172A1 (en) 2018-09-20
IL308112B2 (en) 2025-01-01
EP3595642A4 (en) 2021-05-26
MX2022011881A (es) 2022-11-09
IL269187A (en) 2019-11-28
CA3056231A1 (en) 2018-09-20
US20200016212A1 (en) 2020-01-16
US12138284B2 (en) 2024-11-12
AU2018234632B2 (en) 2024-06-13
CN116003564A (zh) 2023-04-25
JP7461071B2 (ja) 2024-04-03
US11484553B2 (en) 2022-11-01
AU2024219497B2 (en) 2025-08-14
AU2024219497A1 (en) 2024-10-03
JP2020513810A (ja) 2020-05-21
IL308112B1 (en) 2024-09-01
JP2022164658A (ja) 2022-10-27
AU2018234632A1 (en) 2019-10-03
IL269187B1 (en) 2023-12-01
EP3595642A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
MX2022011881A (es) Yap activo dominante, un efector de hippo, induce la accesibilidad a la cromatina y la renovacion de cardiomiocitos.
SG10201810150UA (en) Compositions and methods for enhanced gene expression in cone cells
MY191035A (en) Affinity-oligonucleotide conjugates and uses thereof
MX381640B (es) Metodos y compuestos agonistas de gip.
ZA201507731B (en) Methods and compositions for generating chondrocyte lineage cells and/or cartilage like tissue
BR112017003111A2 (pt) composições e métodos para o tratamento de distúrbios neurológicos
SG10201808835QA (en) Anti-siglec-8 antibodies and methods of use thereof
PH12015502788A1 (en) Antibody formulations and methods
AU201612782S (en) Oral care implement
GB2531952A (en) SC-ß cells and compositions and methods for generating the same
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
MX388960B (es) Una población de células madre mesenquimales enriquecida en integrina a10alta y su uso en la prevención y tratamiento de daño o enfermedad ósea y cartílago.
SG10201803780UA (en) Methods and compositions for sustained immunotherapy
SG10201907875TA (en) Modified meningococcal fhbp polypeptides
MX2017000776A (es) Polipeptidos fhbp meningococicos modificados.
PH12018502303A1 (en) Compositions and methods for bioengineered tissues
MX2018011875A (es) Reprogramacion cardiaca directa mejorada.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MX2017000374A (es) Metodos y composiciones que regulan el crecimiento del pelo.
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
AU201616506S (en) Implant removal tool